4	ì	h	
T		,	

08-27-01

Approved for use through 09/30/2000. OMB 0651-0032 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

UTILITY PATENT APPLICATION TRANSMITTAL

. Please type a plus sign (+) inside this box ightarrow

PC10761A Attorney Docket No. First Named Inventor or Application Identifier Morsey, et al. ANTI-IgE VACCINES EL639818052US Express Mail Label No.

(Only for new nonprovisional applications under 37C.F.R. §1.53(b))

	ADDITION DI EMENTO			ADDRESS TO:	Assistant Co Box Patent A	mmissioner for Patents
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.				ADDRESS TO.	Washington,	
1 X 'F	ee Transmittal Form (e.g., PTO/SB/1)	7)	6.	Microfiche Comp		.5 3
2. Subr	nit an original, and a duplicate for fee procession [Total Pages	ng) 44]	7.	Nucleotide and/or Amir (if applicable, all neces	no Acid Sequ s <i>ary)</i>	ence Submission
(pr	eferred arrangement set forth below) Descriptive title of the Invention			a. Compute	er Readable (Сору 46
-	Cross References to Related Applica			b. Paper Co	opy (identica	I to computer copy
-	Statement Regarding Fed sponsored	3 R&D		c. Stateme	nt verifying id	dentity of above copies
-	Reference in Microfiche Appendix	Г				CATION PARTS
-	Background of the Invention Brief Summary of the Invention	ŀ				neet & document(s))
-	 Brief Summary of the filter Brief Description of the Drawings (if filed) 		8.	<u> </u>		Power of Attorney
-	Detailed Description Claim(s)		9.	37 C.F.R. §3.73(b) (when there is a		Fower of Attorney
-	Abstract of the Disclosure		10.	English Translat		nt (if applicable)
2 5 7		5]	11.	Information Disc		Copies of IDS
=	rawing(s) (35 U.S.C. 11.3)[Total sheet	s 1		Statement (IDS)		Citations
4O	ath or Declaration [Total page	L	12.	Preliminary Am		DED 503)
а			13.	Return Receipt (Should be spec		
t	Copy from a prior application (3	37 CFR	14.	*Small Entity		ement filed in prior application,
	§1.63(d)) (for continuation/divisional with Box	17 completed)		Statement(s)		s still proper and desired
	[Note Box 5 beld			(PTO/SB/09-12 Certified Copy		cument(s)
	i. <u>DELETION OF INVI</u> Signed statement attached de		15.	(if foreign priori		
	inventor(s) named in the prior	application,	l.	(4.1.1.0)		
	see 37 C.F.R. §§1.63(d)(2) an		16.	M others Bris	:t-: Claimad	from United States
5 1	5. Incorporation By Reference (useable if Box 4b is checked)			Other: Price	visional Pate	ent Application 60/228,989,
conv of	ire disclosure of the prior application, the oath or declaration is supplied und	der Box 40, IS	1		d August 30,	
concide	red to be part of the disclosure of the	accompanying				
applicat	ion and is hereby incorporated by refe	sterice dicrem.	[-NO	TE FOR ITEMS 1 & 14: IN ORD	ER TO BE ENTI	TLED TO PAY SMALL ENTITY
				S, A SMALL ENTITY STATEMI NE FILED IN A PRIOR APPLIC		
47 16 o C	ONTINUING APPLICATION, check ap	propriate box, and s	upply ti	he requisite information bel	ow and in a pre	eliminary amendment:
	Continuation Divisional	Continuation	n-in-pa	art (CIP) of prid	or application	No:/
Prior application information: Examiner Group/Art Unit:						
	18			DENCE ADDRESS		
Custom	er Number or Bar Code Label	ustomer No. or Atta	ch bai	r code label here) or	Corresp	ondence address below
Name	Paul H. Ginsburg					
Address	Pfizer Inc					
Address	235 East 42nd Street, 20th Floor					10017 5755
City	New York	State		New York	Zip Code	10017-5755 (212)573-1939
Country	United States Of America	Telephone		(212)573-2369	(Acont)	
	IE (Print/type) Lorraine B. Ling		Reg	istration No. (Attorney/	(Agent)	35,251

Lorraine B. Ling

formaine

NAME (Print/type)

Signature

August 24, 2001

PTO/SB/17 (2/98)
Approved for use through 09/30/2000.
OMB 0651-0032 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

FEE TRANSMITTAL	Application Number				Not Yet Assigned	
	Filing Date				Herewith	
Patent fees are subject to annual revision on October 1.	First Named Inventor				Morsey, et al.	
These are the fees effective October 1, 1997. Small Entity payments must be supported by a small entity statement,		Examiner Name			Not Yet Assigned	
otherwise large entity fees must be paid. See Forms PTO/SB/09-12. See 37 C.F.R. §§ 1.27 and 1.28.	Group/A	rt Unit			Not Yet Assigned	
Total Amount of Payment (\$) 2,798.00	Attorney	Docke	t No.		PC10761A	
METHOD OF PAYMENT (check one)				FEE CAL	CULATION (continued)	
1. The commissioner is hereby authorized to charge	3. ADDITIONAL FEES					
indicated fees and credit any over payments to:	Large Er	Fee .	Small E Fee	Fee		
Deposit Account Number	Fee Code	(\$)	Code	(\$)	Fee Description Fee Paid	
Deposit Account	105	130	205	65	Surcharge – late fee or oath	
Name	127	50	227		Surcharge–late provisional filing fee or cover sheet	
Charge Any Additional Fee Required Under Charge the Issue Fee Set in 37 C.F.R. § 1.18 at the Mailing	139	130	139	130	Non-English specification	
37 C.F.R. §§ 1.16 and 1.17. of the Notice of Allowance.	147	2,520	147	2,520	For filing a request for reexamination	
, <u> </u>	112	920*	112	920*	Requesting publication of SIR prior to	
2. Payment Enclosed: Check Money Order Other	113	1,840*	113	1,840*	Examiner action Requesting publication of SIR after Examiner action	
10m	115	110	215	55	Extension for reply within first month	
FEE CALCULATION 1. BASIC FILING FEE	116	390	216	195	Extension for reply within second	
	147	890	217	445	month Extension for reply within third month	
Large Entity Small Entity	117 118	1,390	218	695	Extension for reply within fourth month	
Code (\$) Code (\$)		,			Constitution of the month	
101 710 201 355 Utility filing fee 710	128	1,890	228	945	Extension for reply within fifth month	
106 320 206 160 Design filing fee	119	310	219	155	Notice of Appeal	
106 320 206 160 Design filing fee 1967 490 207 245 Plant filing fee	120	310	220	155	Filing a brief in support of an appeal	
	121	270	221	135	Request for oral hearing	
114 150 214 75 Provisional filing fee	138	1,510	138	1,510	Petition to institute a public use proceeding	
SUBTOTAL (1) (\$) 710	140	110	240	55	Petition to revive - unavoidable	
2. EXTRA CLAIM FEES	141	1,240	241	620	Petition to revive - unintentional	
Extra Fee from Claims below Fee Paid	142	1,240	242	620	Utility issue fee (or reissue)	
Total Claims 41 -20**= 21 X 18 = 378	143	440	243	220	Design issue fee	
Independent 21 · 3**= 18 X 80 = 1,440.00	144	600	244	300	Plant issue fee	
Claims Multiple Dependent 270 = 270.00	122	130	122	130	Petitions to the Commissioner	
** or number previously paid, if greater; For Reissues, see below Large Entity Small Entity	123	50	123	50	Petitions related to provisional applications	
Fee Fee Fee Fee Description	126	240	126	240	Submission of Information Disclosure Statement	
Code (\$) Code (\$) 103 18 203 9 Claims in excess of 20	581	40	581	40	Recording each patent assignment per property (times number of properties)	
102 80 40 Independent claims in excess of 3	146	710	246	355	Filing a submission after final rejection (37 CFR 1.129(a))	
202 104 270 204 135 Multiple dependent claim, if not paid	149	710	249	355	For each additional invention to be examined (37 CFR 1.129(b))	
109 80 209 40 **Reissue independent claims over	Other Fe	ee (spec	cify)			
original patent 110 18 210 9 **Reissue claims in excess of 20 and over original patent	Other Fee (specify)					
SUBTOTAL (2) (\$) 2,088.00	*Reduce	ed by Ba	asic Filing	Fee Paid	SUBTOTAL (3) (\$)	
SUBMITTED BY					Complete (if Applicable)	
Type or Printed Name Lorraine B. Ling	1 0-4-				Reg. Number 35,251 Deposit Account	
Signature forme & Siz	Date	<u> </u>	August 2	4, 2001	User ID	